2018 American Transplant Congress
Prevention of Hepatitis B Virus Reactivation in HBsAg-Positive Renal Transplant Recipients with Rituximab Treatment
Background: The risk of Hepatitis B virus (HBV) reactivation under immunosuppressant has been well known. Hepatitis B virus reactivation increase patient mortality and graft failure…2018 American Transplant Congress
Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis
BackgroundKidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus-induced liver cirrhosis (LC) remains controversial. This study compared outcomes of KT…2017 American Transplant Congress
A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.
Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background: Hepatitis B virus (HBV)-related liver disease is the major indication of liver transplantation in Asian countries. Combination of anti-hepatitis B immunoglobulin (HBIg) and anti-viral…2017 American Transplant Congress
Hepatitis B Virus Infection Is Associated with Recurrent Nephropathy After Kidney Transplantation.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Hepatitis B virus(HBV) infection can cause HBV associated nephropathy, and is one of the major reasons for secondary nephropathy. We carried out a retrospective…2017 American Transplant Congress
Favorable Long-Term Prognosis of Hepatitis B Surface Antigen Positive Intrahepatic Cholangiocarcinoma for Both Hepatic Resection and Incidental Liver Transplantation via Inhibiting Cancer-Associated Lymphangiogenesis.
Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background: In recent years, a few publications indicated that hepatitis B virus (HBV) infection is associated with the prognosis of patients with ICC after resection.…2017 American Transplant Congress
Blockade of Tim-3 and PD-1 Reverses Dysfunctions of Tumor Infiltrating Lymphocytes in HBV Related Hepatocellular Carcinoma.
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
The immunosuppression of tumor infiltrating lymphocytes (TILs) is associated with rapid progress of hepatitis B virus related hepatocellular carcinoma (HBV-HCC). The inhibition molecules of T…2017 American Transplant Congress
The Evolution of Hepatitis B Surface Antibody (Anti-HBs) Titer of the Kidney Transplant Recipients: A 5-Year Experience Guideline for the Optimal Maintaining Immunization.
Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand
Background: Immunization against hepatitis B virus (HBV) in kidney transplantation (KT) recipients is recommended as KDIGO guideline. Although hepatitis B surface antibody (anti-HBs) titer of…2016 American Transplant Congress
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.
Background:End-stage liver disease secondary to HBV and HCV coinfection is not uncommon in Asia.However,long term outcome of such patients after living donor liver transplantation (LDLT)…2016 American Transplant Congress
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.
IntroductionThe hypothesis of this study was that the long-term outcomes in liver transplant (LTx) patients with hepatitis B virus (HBV) who were treated with nucleos(t)ide…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…
American Transplant Congress abstracts